Main Article Content

Abstract


RÉSUMÉ
Introduction. La cirrhose hépatique est un terrain favorable à l’éclosion d’autres comorbidités. Le but de ce travail était décrire les pathologies de diagnostic endoscopique associées aux varices œsophagiennes. Matériels et Méthodes. Il s’agissait d’une étude transversale à mode de collecte de données rétrospectif sur une période allant de juillet 2008 à juillet 2017 menée dans 3 centres de santé privés dans 3 villes moyennes du Burkina Faso. Résultats. Sur une population de 3556 sujets cirrhotiques, les varices œsophagiennes étaient retrouvées chez 165 patients soit une prévalence de 4,64%. L’âge moyen était de 45,5 ans ±17 avec des extrêmes de 34 et 93 ans. La recherche endoscopique de signes d’hypertension portale (HTP), les manifestations douloureuses thoraco-abdominales et les hémorragies digestives étaient les principaux motifs d’exploration du tube digestif haut. Au niveau œsophagien les lésions mycosiques étaient significativement plus fréquentes (13,93%) chez les patients avec une HTP que dans le groupe sans HTP. Au niveau gastrique, l’ulcère gastrique était significativement plus fréquent chez les patients avec HTP (12,72%) par rapport aux patients sans HTP (7,63%). la maladie ulcéreuse gastroduodénale dans toutes ses localisations était significativement plus fréquente dans le groupe avec HTP (25,45%) par rapport au groupe sans HTP (16,8%). Conclusion. La mycose œsophagienne et la maladie ulcéreuse gastroduodénale sont significativement associées aux signes d’HTP. Des études supplémentaires sont nécessaires pour mieux comprendre cette imbrication. Ces pathologies souvent de découverte fortuite, peuvent influencer l’approche africaine des recommandations de BAVENO 6.
ABSTRACT
Background. Liver cirrhosis is a breeding ground for the outbreak of other comorbidities. The aim of this work was to describe endoscopic pathologies associated with esophageal varices. Materials and methods. This was a cross-sectional study with retrospective data collection mode over a period from July 2008 to July 2017 conducted in 3 private health centers in 3 medium-sized towns in Burkina Faso. Results. In a population of 3556 patients with liver cirrhosis, esophageal varices were found in 165 patients, ie a prevalence of 4.64%. The mean age was 45.5 ± 17 years with extremes of 34 and 93 years. Endoscopic search for signs of portal hypertension (PH), painful thoracoabdominal manifestations, and gastrointestinal bleeding were the main indications for exploring the upper gastrointestinal tract. At the esophageal level, mycotic lesions were significantly more frequent (13.93%) in patients with PH than in the group without PH. At the gastric level, gastric ulcer was significantly more frequent in patients with PH (12.72%) compared to patients without PH (7.63%). peptic ulcer disease in all its locations, it was significantly more frequent in the group with PH (25.45%) than in the group without PH(16.8%). Conclusion. Esophageal mycosis and peptic ulcer disease are significantly associated with the signs of PH. Further studies are needed to better understand this interweaving. These pathologies, often discovered by chance, can influence the African approach to the recommendations of BAVENO 6.

Keywords

Esophageal varices PHT Esophageal mycosis Peptic Ulcer Sub-Saharan Africa Varices œsophagiennes HTP Mycose œsophagienne ulcère gastroduodénal Afrique sub saharienne

Article Details

How to Cite
ZD, O. ., SL, Z. ., M, K. ., R, S. ., A, C. ., KS, S. ., N, S. ., AR, S. ., & A, B. . (2021). Lésions Endoscopiques Liées aux Varices Œsophagiennes dans les Villes Moyennes du Burkina Faso. HEALTH SCIENCES AND DISEASE, 23(1). Retrieved from https://hsd-fmsb.org/index.php/hsd/article/view/3230

References

  1. Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, NEY M, BLASCO H, PROCOPET B, TSOCHATZIS E, WESTBROOK RH, BOSCH J, BERZIGOTTI A, ABRALDES JG, GENESCA J., 2017. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology, 66(6):1980-1988.
  2. BORDEA MA, PIRVAN A, GHEBAN D, SILAGHI C, LUPAN I, SAMAȘCA G, PEPELEA L, JUNIE LM, COSTACHE C., 2020. Infectious Esophagitis in Romanian Children: From Etiology and Risk Factors to Clinical Characteristics and Endoscopic Features. J Clin Med, 9(4):939.
  3. CHANG SS, HU HY., 2013. Helicobacter pylori is not the predominant etiology for liver cirrhosis patients with peptic ulcer disease. Eur J Gastroenterol Hepatol, 25(2):159-65.
  4. CHEN LS, LIN HC, HWANG SJ, LEE FY, HOU MC, LEE SD., 1996. Prevalence of gastric ulcer in cirrhotic patients and its relations to portal hypertension. J Gastroenterol Hepatol, 11: 59–64.
  5. DANIELL HW., 2016. Acid suppressing therapy as a risk factor for Candida esophagitis. Dis Esophagus, 29(5):479-83.
  6. De FRANCHIS R , 2015. on behalf of the Baveno VI Faculty. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 63;743-52
  7. GALLAHER JR, MULIMA G, QURESHI J, SHORES CG, CHARLES AG., 2020. The role of endoscopy after upper gastrointestinal bleeding in sub-Saharan Africa: A prospective observational cohort study. Malawi Med J, 32(3):139-145.
  8. HASSAN EA, ABD EL-REHIM AS, HASSANY SM, AHMED AO, ELSHERBINY NM, MOHAMMED MH.,2014. Fungal infection in patients with end-stage liver disease: low frequency or low index of suspicion. Int J Infect Dis, 23:69-74.
  9. HOVERSTEN P, KAMBOJ AK, KATZKA DA., 2018. Infections of the esophagus: an update on risk factors, diagnosis, and management. Dis Esophagus, 1;31(12).
  10. Institut National de la Statistique et de la Démographie (INSD). Recensement général de la population et de l’habitation de 2006 - Résultats définitifs. Ouagadougou : Ministère de l’économie et des finances ; Juillet 2008.
  11. KIM DJ, KIM HY, KIM SJ, et al., 2008. Helicobacter pylori infection and peptic ulcer disease in patients with liver cirrhosis. Korean J Internal Med, 23:16–21
  12. KIM KY, JANG JY, KIM JW, SHIM JJ, LEE CK, DONG SH, KIM HJ, KIM BH, CHANG YW.,2013. Acid suppression therapy as a risk factor for Candida esophagitis. Dig Dis Sci, 58(5):1282-6.
  13. KIRCHNER GI, BEIL W, BLECK JS, MANNS MP, WAGNER S.,2011. Prevalence of Helicobacter pylori and occurrence of gastroduodenal lesions in patients with liver cirrhosis. Int J Clin Exp Med, 4(1):26-31.
  14. KLIEMANN DA, PASQUALOTTO AC, FALAVIGNA M, GIARETTA T, SEVERO LC.,2008. Candida esophagitis: species distribution and risk factors for infection. Rev Inst Med Trop Sao Paulo, 50(5):261-3
  15. LUO JC, LEU HB, HOU MC, HUANG CC, LIN HC, LEE FY, CHANG FY, CHAN WL, LIN SJ, CHEN JW.,2012. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther, 36(6):542-50.
  16. MARCHETTI B, BOUSTIERE C, CHAPUIS C et coll.,2007. La désinfection du matériel en endoscopie digestive. Fiche de recommandation de la SFED. Acta Endoscopica, vol 37 n°5 : 699-704
  17. MENDEZ-TOVAR LJ, RODRIGUEZ-SANCHEZ JF, MANZANO-GAYOSSO P, HERNANDEZ-HERNANDEZ F, BLANCAS-VALENCIA JM, SILVA-GONZALEZ I.,2019. Candidiasis esofágica en pacientes de un hospital de especialidades [Esophageal candidiasis in patients from a specialty hospital]. Rev Med Inst Mex Seguro Soc, 57(2):74-81.
  18. MERKEL C, ZOLI M, SIRINGO S, et al., 2000. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol, 95:2915-20.
  19. NAITO, Y., YOSHIKAWA, T., OYAMADA, H. et al.,1988. Esophageal candidiasis. Gastroenterol Jpn, 23, 363–370.
  20. OUATTARA A, COFFI D F, RAFIOU EH Y, ASSI C, SORO D, ALLAH-KOUADIO E, LOHOUES KOUACOU. MJ., 2018. Lésions endoscopiques hautes chez le cirrhotique au Centre Hospitalier et Universitaire de Cocody. Rev int sc méd -RISM, 20,4:297-300.
  21. RAJAN SS, SAWE HR, IYULLU AJ, KAALE DA, OLAMBO NA, MFINANGA JA, WEBER EJ., 2019. Profile and outcome of patients with upper gastrointestinal bleeding presenting to urban emergency departments of tertiary hospitals in Tanzania. BMC Gastroenterol, 10;19(1):212.
  22. SICILIANO M, ROSSI L.,1993. La gastropatia congestizia nella cirrosi epatica [Congestive gastropathy in liver cirrhosis]. Minerva Med, 84(7-8):403-8.
  23. SIRINGO S, BURROUGHS AK, BOLONDI L, MUIA A, DI FEBO G, MIGLIOLI M, et al., 1995. Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. J Hepatol, 22:633–641.
  24. SOUSA M, FERNANDES S, PROENÇA L, SILVA AP, LEITE S, SILVA J, PONTE A, RODRIGUES J, SILVA JC, CARVALHO J.,2017. The Baveno VI criteria for predicting esophageal varices: validation in real life practice. Rev Esp Enferm Dig, 109(10):704-707.
  25. THABUT D, BUREAU C, LAYESE R, BOURCIER V, et coll.,2019. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology, 156(4):997-1009.
  26. WU C-S, LIN C-Y, LIAW Y-F., 1995. Helicobacter pylori in cirrhotic patients with peptic ulcer disease: A prospective, case controlled study. Gastrointest End, 42:424-427
  27. ZULLO A, ROMITI A, TOMAO S, HASSAN C, RINALDI V, GIUSTINI M, MORINI S, TAGGI F.,2003. Gastric cancer prevalence in patients with liver cirrhosis. Eur J Cancer Prev, 12(3):179-82

Most read articles by the same author(s)